206 filings
Page 2 of 11
8-K
m15kxu
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm
8-K
3nv7xvd
27 Apr 23
Non-Dilutive and Strengthens Balance Sheet
4:43pm
8-K
z81nu1
10 Mar 23
Regulation FD Disclosure
4:43pm
8-K
q7ymiz3lo6f
7 Mar 23
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
o90u2b u309
7 Feb 23
Results of Operations and Financial Condition
4:06pm
ARS
ine1a5zhuq t7fucw
7 Feb 23
Annual report to shareholders
3:01pm
DEFA14A
n0gx7d
20 Jan 23
Additional proxy soliciting materials
4:05pm
8-K
5xlxpmfueexyo70hh4
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
u3i6szpw
26 Aug 22
Entry into a Material Definitive Agreement
4:10pm
424B5
bq6jk6ke rdziee0s63m
26 Aug 22
Prospectus supplement for primary offering
4:06pm
8-K
z24o jafnlxjhoj6n
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
6nnui
22 Jun 22
Other Events
6:22am
8-K
irv5d8
17 May 22
Entry into a Material Definitive Agreement
4:37pm
S-8
f2in1r1
9 May 22
Registration of securities for employees
4:20pm
8-K
lvvjz28o
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm